Drug Profile
GSK 3858279
Alternative Names: GSK-3858279Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Chemokine CCL17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Pain in Germany (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Pain in Germany (SC)
- 10 Nov 2023 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase-I trial in Pain presented at the ACR Convergence 2023 (ACR-ARP-2023)